ライフサイエンスコーパス: GVL effect

1 f EL4 cells and B10.BR DLI had a more modest GVL effect.

2 utologous BMT may be a means for providing a GVL effect.

3 GVHD but eliminates, at least partially, the GVL effect.

4 in an Ag-dependent manner while sparing the GVL effect.

5 sulting in the concomitant inhibition of the GVL effect.

6 ockade of NKG2D significantly suppressed the GVL effect.

7 or GVHD induction while less critical to the GVL effect.

8 (-/-)) Tconv mediate a robust and beneficial GvL effect.

9 T cells attack leukemia cells, mediating the GVL effect.

10 3 signaling reduces GVHD without loss of the GVL effect.

11 e in WT1 expression, suggesting a WT1-driven GVL effect.

12 monstrated that perforin is critical for the GVL effect.

13 ty Ag (miHAg) with a proven role in GVHD and GVL effect.

14 ts effective GVHD protection while enhancing GVL effects.

15 KCalpha spared T-cell cytotoxic function and GVL effects.

16 xhaustion, or apoptosis, resulting in strong GVL effects.

17 ng particularly on enhancing the therapeutic GVL effects.

18 tologic malignancies through T cell-mediated GVL effects.

19 ecognition for preventing GVHD while sparing GVL effects.

20 to host antigens and maintaining beneficial GVL effects.

21 y administration of DLI can mediate powerful GVL effects.

22 n approach to inhibiting GVHD that optimizes GVL effects.

23 a STAT6-dependent mechanism while preserving GVL effects.

24 eserving a beneficial graft-versus-leukemia (GVL) effect.

25 recipient and mediate the graft-vs-leukemia (GVL) effect.

26 VHD while sparing the graft-versus-leukemia (GVL) effect.

27 or a cancer-specific graft-versus-leukemia (GVL) effect.

28 ity, resulting in the graft-versus-leukemia (GVL) effect.

29 demonstration of the graft-versus-leukemia (GVL) effect.

30 IL-11 can maintain a graft-versus-leukemia (GVL) effect.

31 capable of providing graft-versus-leukemia (GVL) effects.

32 e mediated allogeneic graft-versus-leukemia (GVL) effects.

33 reactive and mediate graft-versus-leukemia (GVL) effects.

34 c and fail to mediate graft-versus-leukemia (GVL) effects.

35 that does not impair graft-versus-leukemia (GVL) effects.

36 The therapeutic GVL effect after allogeneic stem cell transplantation is

37 to respond to virus infection and to induce GVL effect after BMT.

38 CD45 epitopes may be useful in restoring the GVL effect after HLA-A2-mismatched haploidentical transp

39 Natural killer (NK) cells mediate GVL effects after allogeneic hematopoietic cell transpla

40 that perforin is a crucial pathway mediating GVL effects after G-CSF-mobilized PBSCT.

41 WT1) contributes to a graft-versus-leukemia (GVL) effect after allogeneic stem-cell transplantation (

42 ctivity and preserved graft-versus-leukemia (GVL) effects after allogeneic BMT (70% vs 10%; P <.01).

43 ounterparts; however, graft-versus-leukemia (GVL) effects after allogeneic stem cell transplantation

44 Furthermore, IFN-gamma is involved in the GVL effect against EL4 leukemia, demonstrating that prot

45 n the Y chromosome contribute to a selective GVL effect against myeloid and lymphoid leukemias after

46 GVL effects against EL4 depended on CD8-mediated allorea

47 ost lymphohematopoietic reactions, including GVL effects against host leukemia/lymphoma cells, of CD8

48 In contrast, DNAM-1 was not critical for GVL effects against ligand (CD155) expressing and nonexp

49 ut did not abrogate a graft-versus-leukemia (GVL) effect against C1498, a myeloid leukemia.

50 t donor CD8-dependent graft-versus-leukemia (GVL) effects against EL4 (H-2(b)) leukemia/lymphoma can

51 on of TK-transduced T lymphocytes may induce GVL effect and allow for their subsequent selective elim

52 Both GVL effects and the inhibitory effect of IL-12 on GVHD w

53 8+ T cells mediate both a graft-vs-leukemia (GVL) effect and graft-vs-host disease (GVHD).

54 s may contribute to a graft-versus-leukemia (GVL) effect and to graft-versus-host disease (GVHD).

55 The graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD)-induci

56 atibility, graft-versus-host disease (GVHD), GVL effect, and immune reconstitution after transplant.

57 on, but GVHD is tightly linked to beneficial GVL effects, and removal of donor T cells that cause GVH

58 ty and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconst

59 The graft-versus-leukemia (GVL) effect associated with allogeneic blood and marrow

60 s through T-cell-mediated graft-vs-leukemia (GVL) effects but often leads to severe graft-vs-host dis

61 ing donor cell engraftment and improving the GVL effect, but they should not recognize host nonhemato

62 on can provide a curative graft-vs-leukemia (GVL) effect, but there is a significant risk of graft-vs

63 vely augment T-cell responses that promote a GVL effect by adoptive immunotherapy with T-cell clones

64 iller (NK) cells can be recruited to mediate GVL effect by careful mismatching on the killer-cell imm

65 Augmenting the GVL effect by the adoptive transfer of donor-derived B-A

66 empted to improve the graft-versus-leukemia (GVL) effect by generating allorestricted cytotoxic T lym

67 ell-mediated graft-versus-leukemia/lymphoma (GVL) effects, derived from the graft or subsequent adopt

68 sex combinations, demonstrating a selective GVL effect distinct from that contributed by GVHD.

69 treatment with HY-iTregs still preserved the GVL effect even against pre-established leukemia.

70 st disease (GVHD) and graft-versus-leukemia (GVL) effects following bone marrow transplantation (BMT)

71 offers a novel approach to the separation of GVL effects from GVHD.

72 pproach to separating graft-versus-lymphoma (GVL) effects from graft-versus-host disease (GVHD) in mi

73 The most direct evidence of the GVL effect has been provided by the efficacy of donor le

74 A graft-versus-leukemia (GVL) effect has been considered a major factor responsib

75 The intrinsic graft-versus-leukemia (GvL) effect, however, is the desirable curative benefit.

76 whether G-CSF-mobilized PBSC maintain their GVL effect in a murine allogeneic transplant model (B6 -

77 The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transp

78 ens implicated in the graft-versus-leukemia (GVL) effect in chronic myeloid leukemia (CML) include WT

79 er IL-18 can maintain graft-versus-leukemia (GVL) effect in this context.

80 ile preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD mo

81 y, IFN-gamma enhances graft-versus-leukemia (GVL) effects in both models.

82 The GVL effect is directed against minor histocompatibility

83 separation of GVL from GVHD, suggesting the GVL effect is due to largely unopposed Tcon alloantigen

84 h preservation of the graft-versus-leukemia (GVL) effect is a crucial step to improve the overall sur

85 ) without loss of the graft-versus-leukemia (GVL) effect is the holy grail of hematopoietic cell tran

86 suggest that donor-derived NK cell-mediated GVL effects may be improved by sensitizing residual quie

87 The late loss of DLI-mediated GVL effects may reflect the eventual loss of donor-deriv

88 days) was more potent than the Tc2-mediated GVL effect (mean survival of 20.5 days; Tc1 > Tc2, p = 0

89 doses of 2 to 2.5 x 10(7), the Tc1-mediated GVL effect (mean survival of 34.2 days) was more potent

90 majority of mixed chimeras, with significant GvL effects mediated by both CD4(+) and CD4(-) cells.

91 GVL effects mediated by granzyme-positive CD8 T cells we

92 ignancies is due to a graft-versus-leukemia (GVL) effect mediated by donor T cells that recognize rec

93 The graft-versus-leukemia (GVL) effect mediated by the allogeneic graft, however, i

94 erapy and from potent graft-versus-leukemia (GVL) effects mediated by donor immunity.

95 The graft-versus-leukemia (GVL) effect, mediated by donor T cells, has revolutioniz

96 Finally, we found that the in vivo GVL effect of CD18-/- donor T cells was largely preserve

97 iously unidentified means for augmenting the GVL effect of delayed donor lymphocyte infusion.

98 dministration of anti-B7 mAbs may impair the GVL effect of DLI and that the forced expression of B7-1

99 of B7-1 on EL4 cells markedly augmented the GVL effect of DLI, in contrast to the forced expression

100 e first time that GVHD-inducing activity and GVL effects of allogeneic CD8 T cells can be separated b

101 icant protective effect against GVHD, marked GVL effects of allogeneic T cells against EL4 were obser

102 approach to inhibiting GVHD while preserving GVL effects of alloreactivity.

103 The graft-versus-leukemia (GVL) effect of donor cells (against A20 tumor cells) was

104 Conversely, CD8(+) T cells induce GVL effects primarily through the use of perforin and mi

105 cking antibodies are not only possible novel GVL effect-sparing therapeutics for the treatment of GVH

106 l-recognized graft-versus-leukemia/lymphoma (GVL) effect that is mediated by donor-derived alloreacti

107 T cells mediate this graft-versus-leukemia (GVL) effect, the influence of DLI on the T cell compartm

108 from the failure of a graft-versus-leukemia (GVL) effect to eradicate minimal residual disease.

109 n (BMT) relies on the graft-versus-leukemia (GVL) effect to eradicate residual tumor cells through im

110 Prevention of GVHD while preserving GVL effect using third-party regulatory T cells is under

111 The magnitude of the GVL effect was dependent on the level of major histocomp

112 eficient donor T cells demonstrated that the GVL effect was perforin dependent.

113 asoning that AZA might selectively augment a GVL effect, we studied the immunologic sequelae of AZA a

114 igate strategies that retain and enhance the GVL effects while limiting toxicity from this therapy, a

115 uvers to optimize the graft-versus-leukemia (GVL) effect while preventing graft-versus-host-disease (

116 full donor chimerism and mediated a powerful GVL effect with complete protection (100% survival) agai

117 infusion (DLI) post-BMT can mediate a potent GVL effect with less graft-vs-host disease (GVHD) than w

118 ll subsets mediated a graft-versus-leukemia (GVL) effect with reduced graft-versus-host disease (GVHD

119 ansplantation as a mechanism of augmenting a GVL effect without a concomitant increase in GVHD.

120 rced expression of B7-1 ligands stimulates a GVL effect without adversely affecting the GVHD lethalit

121 Strategies that augment a GVL effect without increasing the risk of GVHD are requi

122 donor lymphocyte infusions (DLI) to mediate GVL effects without GVHD in mixed chimeras prepared with

123 ons (DLIs) can induce graft-versus-leukemia (GVL) effects without graft-versus-host disease (GVHD).

124 h to achieve graft-versus-leukemia/lymphoma (GVL) effects without GVHD, we have observed surprisingly